Scarica l'app Stockscreener
33.80
9.21%
2.85
Dopo l'orario di chiusura:
33.50
-0.30
-0.89%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$30.95
Aprire:
$31.28
Volume 24 ore:
23.45M
Relative Volume:
2.16
Capitalizzazione di mercato:
$13.21B
Reddito:
$3.14B
Utile/perdita netta:
$-3.36B
Rapporto P/E:
-3.8717
EPS:
-8.73
Flusso di cassa netto:
$-4.03B
1 W Prestazione:
+14.73%
1M Prestazione:
+39.78%
6M Prestazione:
+33.07%
1 anno Prestazione:
-14.56%
Intervallo 1D:
$31.17
$34.25
Intervallo di 1 settimana:
$28.66
$34.25
Portata 52W:
$22.28
$48.92
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
33.80 | 12.09B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-12 | Iniziato | Jefferies | Hold |
| 2025-03-13 | Iniziato | Citigroup | Neutral |
| 2025-02-18 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-01-29 | Downgrade | Goldman | Buy → Neutral |
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
CEPI to Fund Pivotal Phase 3 Trial for Moderna's mRNA Pandemic Influenza Vaccine Candidate - Cape Cod Times
Moderna Highlights Seasonal Flu and H5 Pandemic Flu Candidates at IDWeek 2025 - Daytona Beach News-Journal
Moderna Stock (MRNA) News, Forecasts and Analysis: CEPI Bird Flu Funding, FDA Scrutiny and the 2026 Outlook (Dec. 20, 2025) - ts2.tech
Ideas Watch: How buybacks impact Moderna Inc. stock valueJuly 2025 Levels & Daily Momentum Trading Reports - Улправда
Why Is Moderna (MRNA) Stock Rocketing Higher Today - Finviz
MRNA to Get CEPI Funding for Phase III Study on Pandemic Influenza Jab - Finviz
CEPI to fund Moderna’s mRNA pandemic flu candidate - The Pharma Letter
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Marion Star
There's No Escaping Moderna, Inc.'s (NASDAQ:MRNA) Muted Revenues Despite A 28% Share Price Rise - simplywall.st
Down 80%, Should You Buy the Dip on Moderna? - AOL.com
Inside Biotech: Moderna’s bird flu funding brings pandemic preparedness back into view - Proactive financial news
Moderna gets funding for bird flu shot after HHS ends contract - The Boston Globe
Moderna gets funding for H5 pandemic influenza vaccine - BioPharma Dive
Moderna (MRNA) Valuation Check as CEPI Backs Phase 3 H5 Bird Flu Vaccine with $54.3 Million Funding - Yahoo Finance
Moderna, Inc. (MRNA): A Bull Case Theory - Finviz
Moderna, Inc. (MRNA): A bull case theory - MSN
Moderna's $54M Lifeline: Bird Flu Bet Revived After U.S. Pullbac - GuruFocus
Moderna's $54M Lifeline: Bird Flu Bet Revived After U.S. Pullback - Yahoo Finance
Why Moderna (MRNA) Stock Is Up Today - Finviz
After HHS walks away from mRNA vaccine research, Moderna finds $54M lifeline - Scripps News
Moderna gets $54.3 million investment for bird flu vaccine - upi.com
Moderna secures up to $54.3 million funding for bird flu vaccine from global coalition - Reuters
Moderna Gets Bird Flu Shot Funding After HHS Ends Contract - Bloomberg.com
Moderna Scores $54 Million From CEPI To Fund Bird Flu Vaccine - BioSpace
Moderna (MRNA) Advances with $54.3M Boost for H5 Flu Vaccine Tri - GuruFocus
Moderna (MRNA) Secures $54.3M Funding for Bird Flu Vaccine Trial - GuruFocus
Biotech Leader Afeyan Warns That ‘Scientific Method Is Under Attack’ In The US - Citeline News & Insights
New mRNA flu shot moves to major trial in push to blunt the next pandemic - Stock Titan
Discipline and Rules-Based Execution in MRNA Response - news.stocktradersdaily.com
University of TorontoU of T and Moderna partner to advance vaccine science, cancer treatment and AI-driven therapeutics - Education News Canada
Key facts: French study confirms Moderna vaccine reduces COVID-19 deaths; Moderna to present at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Moderna (MRNA) Stock Trades Up, Here Is Why - Finviz
Moderna (NASDAQ:MRNA) Trading 5.3% HigherShould You Buy? - MarketBeat
Is Moderna Inc (MRNA) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
CHMP Backs EU Approval of MRNA's New COVID-19 Vaccine mNexspike - Finviz
Moderna Announces First Patient Dosed in Phase 1/2 Study of Investigational T-Cell Engager for Multiple Myeloma - Erie Times-News
Moderna (MRNA) Is Up 5.9% After EMA Backs New mNEXSPIKE VaccineHas The Bull Case Changed? - Yahoo Finance
Moderna (MRNA) swaps 4.33M employee options for 1.67M new grants - Stock Titan
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):